Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | GPR142 | Q7Z601 | 4/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677776 | 0.73 | NAMPT (0.44) | NAMPT | |
| SCHEMBL18079544 | 0.73 | HDAC2 (0.55) | TP53 | |
| SCHEMBL13739161 | 0.73 | HDAC2 (0.70) | — | |
| SCHEMBL27723722 | 0.71 | MAPK13 (0.53) | — | |
| SCHEMBL9466671 | 0.70 | MAPT (0.65) | NPC1RAB9ASMN1; SMN2MAPTTGM2 | |
| SCHEMBL22668561 | 0.70 | ADCY1 (0.51) | NPC1RAB9ALMNA | |
| SCHEMBL13595574 | 0.70 | KDM4E (0.58) | NAMPTTRPV1 | |
| SCHEMBL16569138 | 0.70 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2TRPV1TGM2 | |
| SCHEMBL4526775 | 0.69 | RAB9A (0.71) | NAMPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL14147225 | 0.69 | TSHR (0.55) | NAMPTSMN1; SMN2LMNATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | NAMPT 1049/4885NPC1 1693/4885RAB9A 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.